Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
Pea
F
F
Institute of Clinical Pharmacology & Toxicology, Department of Experimental and Clinical Pathology and Medicine, Medical School, University of Udine, Italy.
Furlanut
M
M
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D016022:Case-Control Studies; D016638:Critical Illness; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D064704:Levofloxacin; D008297:Male; D020714:Maximum Tolerated Dose; D015242:Ofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D012016:Reference Values; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin